Abstract:Nucleos(t)ide analog therapy blocks DNA synthesis by the hepatitis B virus (HBV) reverse transcriptase and can control the infection, but treatment is life-long and has high costs and unpredictable long-term side effects. The profound suppression of HBV by the nucleos(t)ide analogs and their ability to cure some patients indicates that they can push HBV to the brink of extinction. Consequently, more patients could be cured by suppressing HBV replication further using a new drug in combination with the nucleos(t)ide analogs. The HBV ribonuclease H (RNAseH) is a logical drug target because it is the second of only two viral enzymes that are essential for viral replication, but it has not been exploited, primarily because it is very difficult to produce active enzyme. To address this difficulty, we expressed HBV genotype D and H RNAseHs in E. coli and enriched the enzymes by nickel-affinity chromatography. HBV RNAseH activity in the enriched lysates was characterized in preparation for drug screening. Twenty-one candidate HBV RNAseH inhibitors were identified using chemical structure-activity analyses based on inhibitors of the HIV RNAseH and integrase. Twelve anti-RNAseH and anti-integrase compounds inhibited the HBV RNAseH at 10 µM, the best compounds had low micromolar IC(50) values against the RNAseH, and one compound inhibited HBV replication in tissue culture at 10 µM. Recombinant HBV genotype D RNAseH was more sensitive to inhibition than genotype H. This study demonstrates that recombinant HBV RNAseH suitable for low-throughput antiviral drug screening has been produced. The high percentage of compounds developed against the HIV RNAseH and integrase that were active against the HBV RNAseH indicates that the extensive drug design efforts against these HIV enzymes can guide anti-HBV RNAseH drug discovery. Finally, differential inhibition of HBV genotype D and H RNAseHs indicates that viral genetic variability will be a factor during drug development.

Hammerhead Ribozymes Suppress HBV(adr) in HepG2 Cells

Effect of Ribozymes on Inhibiting Expression of HBV Mrna in HepG2 Cells

Efficient Inhibition of Hepatitis B Virus Replication by Hammerhead Ribozymes Delivered by Hepatitis Delta Virus.

Investigation on Activities of Hammerhead Ribozyme Embedded in Genomic RNA of Hepatitis Delta Virus

Ribozyme Delivered by Hepatitis Delta Virus Inhibits Hepatitis B Virus Replication in Mice

Inhibition of Hepatitis B Virus Gene Expression by Single and Dual Small Interfering RNA Treatment

Inhibition of Dual-Target Ribozyme Against HBV on HBeAg in HHCC Cells

Intracellular Application of Two-Unit Ribozyme Gene Against Hepatitis B Virus

Anti-viral activity of hairpin ribozyme directed against HBV core region in vitro

INHIBITION OF HEPATITIS B VIRUS BY COMBINED Sirnas IN VITRO

Preliminary Study on the Inhibition of HBeAg Expression in Cells by Ribozyme

Inhibition of Hepatitis B Virus Replication by Recombinant Small Interfering RNAs.

DNAzymes in vitro inhibit the expression of hepatitis B virus genes

Effective Inhibition of Expression of Hepatitis B Virus Genes by DNAzymes.

The Hepatitis B Virus Ribonuclease H Is Sensitive to Inhibitors of the Human Immunodeficiency Virus Ribonuclease H and Integrase Enzymes

Design and activity assessment of HDV ribozymes to trans-cleave HCV RNA

Two-unit ribozyme mediated cleavage against hepatitis B virus

Activity of Hdv Ribozymes to Trans-Cleave Hcv Rna

Inhibition of HBV Core Antigen Gene Expression in Human Embryonic Kidney Cell Line AD293 by Plasmid-Based RNAi

Inhibition of Hepatitis B Virus Replication by Stably Expressed Shrna

[Construction of the Expression Vectors of HDV Ribozymes and Their Intracellular Inhibiting Activity Against HCV RNA].